GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDY) » Definitions » 10-Year Sharpe Ratio

SHTDY (Sinopharm Group Co) 10-Year Sharpe Ratio : N/A (As of Jul. 15, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Sinopharm Group Co 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2025-07-15), Sinopharm Group Co's 10-Year Sharpe Ratio is Not available.


Competitive Comparison of Sinopharm Group Co's 10-Year Sharpe Ratio

For the Medical Distribution subindustry, Sinopharm Group Co's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's 10-Year Sharpe Ratio Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's 10-Year Sharpe Ratio falls into.


;
;

Sinopharm Group Co 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.


Sinopharm Group Co  (OTCPK:SHTDY) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Sinopharm Group Co 10-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's 10-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research 06-17-2024

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016